At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 100 enrolled
Drug / intervention
Golimumabdrug
Likely dose
Golimumab 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis
In Brief
A Phase 4 clinical trial evaluating Golimumab for Spondylitis, Ankylosing and Arthritis, Psoriatic. Completed, enrolled 100 participants across 9 sites.
Detailed Summary
The purpose of this study is to assess the safety of subcutaneous (SC) golimumab in participants with active Ankylosing Spondylitis (AS) or Psoriatic Arthritis (PsA) over 24 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpondylitis, Ankylosing, Arthritis, Psoriatic
CountriesIndia
Collaborators--
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartJan 2019
Primary CompletionNov 2021
TodayJul 2026
First PostedNov 7, 2018
Enrollment StartJan 7, 2019
Primary CompletionNov 15, 2021
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 7.7 years ago
Interventions
Golimumabdrug
Participants will receive golimumab 50 mg SC injections at Week 0 and q4w thereafter through Week 24.